Abstract:
Background:
Stapokibart is a novel anti-interleukin-4 receptor α subunit monoclonal antibody approved for moderate-to-severe atopic dermatitis (AD) in adults.
Objective:
To evaluate the feasibility of extending dosing interval of stapokibart based on efficacy response in AD.
Methods:
In this ongoing, multicenter, open-label, single-arm trial (NCT06116565), stapokibart 300 mg was administered subcutaneously every 2 weeks (Q2W) for 12 weeks, followed by dosing interval adjustments at weeks 12 and 36. At week 12, nonresponders (failed to achieve ≥50% improvement from baseline in Eczema Area and Severity Index [EASI-50]) were withdrawn, fast responders (achieved ≥75% improvement from baseline in EASI score [EASI-75] or Investigator’s Global Assessment score of 0/1 [IGA 0/1]) were extended to every 4 weeks (Q4W), and slow responders (achieved EASI-50 but not EASI-75 or IGA 0/1) continued Q2W dosing. At week 36, fast responders achieving ≥90% improvement from baseline in EASI score (EASI-90) or IGA 0/1 were further extended to every 8 weeks (Q8W) (Q2W-Q4W-Q8W group), slow responders with EASI-90 or IGA 0/1 were extended to Q4W (Q2W-Q2W-Q4W group), and others maintained their prior dosing through week 52 (Q2W-Q4W-Q4W and Q2W-Q2W-Q2W groups).
Results:
As of April 7, 2025, 256 and 200 patients completed 12 and 36 weeks of treatment, respectively. In the Q2W-Q4W-Q8W group, 93.0%, 73.7%, and 70.7% of patients sustained EASI-75, IGA 0/1, and ≥4-point reduction in weekly average of daily Peak Pruritus Numerical Rating Scale at week 52, versus 99.2%, 90.1%, and 71.1% at week 36, and 98.3%, 54.5%, and 58.3% at week 12. These response rates in the Q2W-Q4W-Q4W group were 96.2%, 23.1%, and 38.5% at week 12, versus 81.8%, 63.6%, and 72.7% at week 52. In the Q2W-Q2W-Q4W group, these responses were achieved in 95.8%, 83.3%, and 77.3% of patients at week 36, increasing to 100%, 80.0%, and 80.0% at week 52. In the Q2W-Q2W-Q2W group, 84.6%, 23.1%, and 71.4% of patients progressively achieved these responses at week 52 with continued standard dosing. The overall incidence of treatment-emergent adverse events was 78.6%, mostly mild or moderate.
Conclusion:
Extending dosing interval of stapokibart based on efficacy response demonstrated sustained efficacy and favorable safety in AD.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
0.00 MB2.69 MB 
